Hemoglobin-based oxygen carrier mitigates transfusion-mediated pancreas cancer progression

Karen K. Lo, Erik A. Bey, Biswantha Patra, Douglas D. Benson, David A. Boothman, Christopher C. Silliman, Carlton C. Barnett

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Perioperative blood transfusion in pancreatic cancer patients is linked to decreased survival; however, a causal mechanism has not been determined. Previously we have shown that the plasma fraction of stored packed red blood cells (pRBCs) promotes pancreas cancer progression and associated morbidity. We hypothesize these untoward effects will be mitigated by use of a hemoglobin-based oxygen carrier (HBOC). Methods: Cytokines and growth factors were measured in the plasma fraction from stored pRBCs and in an HBOC via cytokine array followed by formal enzyme-linked immunosorbent assay (ELISA). In an immunocompetent murine model, pancreas cancer progression was determined in vivo by bioluminescence, tumor weight, and number of metastases. Results: Elevated levels of epidermal growth factor (EGF), platelet-derived growth factor BB (PDGF-BB), and regulated upon activation, normal T cell expressed and secreted (RANTES) were present in the plasma fraction of stored pRBCs, but were not found in the HBOC. Intravenous delivery of plasma fraction to mice with pancreatic cancer resulted in increased bioluminescence activity compared with mice that received HBOC. Metastatic events and pancreatic primary tumor weights were significantly higher in animals receiving plasma fraction from stored pRBCs compared with animals receiving HBOC. Conclusions: Intravenous receipt of the acellular plasma fraction of stored pRBCs promotes pancreatic cancer progression in an immunocompetent mouse model. These untoward events are mitigated by use of an HBOC.

Original languageEnglish (US)
Pages (from-to)2073-2077
Number of pages5
JournalAnnals of Surgical Oncology
Volume20
Issue number6
DOIs
StatePublished - Jun 2013

Fingerprint

Pancreatic Neoplasms
Hemoglobins
Oxygen
Erythrocytes
Tumor Burden
Cytokines
Epidermal Growth Factor
Blood Transfusion
Intercellular Signaling Peptides and Proteins
Enzyme-Linked Immunosorbent Assay
Neoplasm Metastasis
Morbidity
T-Lymphocytes
Survival

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Lo, K. K., Bey, E. A., Patra, B., Benson, D. D., Boothman, D. A., Silliman, C. C., & Barnett, C. C. (2013). Hemoglobin-based oxygen carrier mitigates transfusion-mediated pancreas cancer progression. Annals of Surgical Oncology, 20(6), 2073-2077. https://doi.org/10.1245/s10434-012-2842-0

Hemoglobin-based oxygen carrier mitigates transfusion-mediated pancreas cancer progression. / Lo, Karen K.; Bey, Erik A.; Patra, Biswantha; Benson, Douglas D.; Boothman, David A.; Silliman, Christopher C.; Barnett, Carlton C.

In: Annals of Surgical Oncology, Vol. 20, No. 6, 06.2013, p. 2073-2077.

Research output: Contribution to journalArticle

Lo, KK, Bey, EA, Patra, B, Benson, DD, Boothman, DA, Silliman, CC & Barnett, CC 2013, 'Hemoglobin-based oxygen carrier mitigates transfusion-mediated pancreas cancer progression', Annals of Surgical Oncology, vol. 20, no. 6, pp. 2073-2077. https://doi.org/10.1245/s10434-012-2842-0
Lo, Karen K. ; Bey, Erik A. ; Patra, Biswantha ; Benson, Douglas D. ; Boothman, David A. ; Silliman, Christopher C. ; Barnett, Carlton C. / Hemoglobin-based oxygen carrier mitigates transfusion-mediated pancreas cancer progression. In: Annals of Surgical Oncology. 2013 ; Vol. 20, No. 6. pp. 2073-2077.
@article{22c2d2138982468791c9cc017310934c,
title = "Hemoglobin-based oxygen carrier mitigates transfusion-mediated pancreas cancer progression",
abstract = "Background: Perioperative blood transfusion in pancreatic cancer patients is linked to decreased survival; however, a causal mechanism has not been determined. Previously we have shown that the plasma fraction of stored packed red blood cells (pRBCs) promotes pancreas cancer progression and associated morbidity. We hypothesize these untoward effects will be mitigated by use of a hemoglobin-based oxygen carrier (HBOC). Methods: Cytokines and growth factors were measured in the plasma fraction from stored pRBCs and in an HBOC via cytokine array followed by formal enzyme-linked immunosorbent assay (ELISA). In an immunocompetent murine model, pancreas cancer progression was determined in vivo by bioluminescence, tumor weight, and number of metastases. Results: Elevated levels of epidermal growth factor (EGF), platelet-derived growth factor BB (PDGF-BB), and regulated upon activation, normal T cell expressed and secreted (RANTES) were present in the plasma fraction of stored pRBCs, but were not found in the HBOC. Intravenous delivery of plasma fraction to mice with pancreatic cancer resulted in increased bioluminescence activity compared with mice that received HBOC. Metastatic events and pancreatic primary tumor weights were significantly higher in animals receiving plasma fraction from stored pRBCs compared with animals receiving HBOC. Conclusions: Intravenous receipt of the acellular plasma fraction of stored pRBCs promotes pancreatic cancer progression in an immunocompetent mouse model. These untoward events are mitigated by use of an HBOC.",
author = "Lo, {Karen K.} and Bey, {Erik A.} and Biswantha Patra and Benson, {Douglas D.} and Boothman, {David A.} and Silliman, {Christopher C.} and Barnett, {Carlton C.}",
year = "2013",
month = "6",
doi = "10.1245/s10434-012-2842-0",
language = "English (US)",
volume = "20",
pages = "2073--2077",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Hemoglobin-based oxygen carrier mitigates transfusion-mediated pancreas cancer progression

AU - Lo, Karen K.

AU - Bey, Erik A.

AU - Patra, Biswantha

AU - Benson, Douglas D.

AU - Boothman, David A.

AU - Silliman, Christopher C.

AU - Barnett, Carlton C.

PY - 2013/6

Y1 - 2013/6

N2 - Background: Perioperative blood transfusion in pancreatic cancer patients is linked to decreased survival; however, a causal mechanism has not been determined. Previously we have shown that the plasma fraction of stored packed red blood cells (pRBCs) promotes pancreas cancer progression and associated morbidity. We hypothesize these untoward effects will be mitigated by use of a hemoglobin-based oxygen carrier (HBOC). Methods: Cytokines and growth factors were measured in the plasma fraction from stored pRBCs and in an HBOC via cytokine array followed by formal enzyme-linked immunosorbent assay (ELISA). In an immunocompetent murine model, pancreas cancer progression was determined in vivo by bioluminescence, tumor weight, and number of metastases. Results: Elevated levels of epidermal growth factor (EGF), platelet-derived growth factor BB (PDGF-BB), and regulated upon activation, normal T cell expressed and secreted (RANTES) were present in the plasma fraction of stored pRBCs, but were not found in the HBOC. Intravenous delivery of plasma fraction to mice with pancreatic cancer resulted in increased bioluminescence activity compared with mice that received HBOC. Metastatic events and pancreatic primary tumor weights were significantly higher in animals receiving plasma fraction from stored pRBCs compared with animals receiving HBOC. Conclusions: Intravenous receipt of the acellular plasma fraction of stored pRBCs promotes pancreatic cancer progression in an immunocompetent mouse model. These untoward events are mitigated by use of an HBOC.

AB - Background: Perioperative blood transfusion in pancreatic cancer patients is linked to decreased survival; however, a causal mechanism has not been determined. Previously we have shown that the plasma fraction of stored packed red blood cells (pRBCs) promotes pancreas cancer progression and associated morbidity. We hypothesize these untoward effects will be mitigated by use of a hemoglobin-based oxygen carrier (HBOC). Methods: Cytokines and growth factors were measured in the plasma fraction from stored pRBCs and in an HBOC via cytokine array followed by formal enzyme-linked immunosorbent assay (ELISA). In an immunocompetent murine model, pancreas cancer progression was determined in vivo by bioluminescence, tumor weight, and number of metastases. Results: Elevated levels of epidermal growth factor (EGF), platelet-derived growth factor BB (PDGF-BB), and regulated upon activation, normal T cell expressed and secreted (RANTES) were present in the plasma fraction of stored pRBCs, but were not found in the HBOC. Intravenous delivery of plasma fraction to mice with pancreatic cancer resulted in increased bioluminescence activity compared with mice that received HBOC. Metastatic events and pancreatic primary tumor weights were significantly higher in animals receiving plasma fraction from stored pRBCs compared with animals receiving HBOC. Conclusions: Intravenous receipt of the acellular plasma fraction of stored pRBCs promotes pancreatic cancer progression in an immunocompetent mouse model. These untoward events are mitigated by use of an HBOC.

UR - http://www.scopus.com/inward/record.url?scp=84878214078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878214078&partnerID=8YFLogxK

U2 - 10.1245/s10434-012-2842-0

DO - 10.1245/s10434-012-2842-0

M3 - Article

C2 - 23328973

AN - SCOPUS:84878214078

VL - 20

SP - 2073

EP - 2077

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 6

ER -